Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Mianserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.94 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.94 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.94 |
| ▸ | DRD3 | P35462 | 8/20 | 0.94 |
| ▸ | HTR2A | P28223 | 7/20 | 0.94 |
| ▸ | DRD2 | P14416 | 7/20 | 0.94 |
| ▸ | HTR1A | P08908 | 6/20 | 0.94 |
| ▸ | HTR2C | P28335 | 5/20 | 0.94 |
| ▸ | HTR2B | P41595 | 5/20 | 0.94 |
| ▸ | DRD4 | P21917 | 4/20 | 0.94 |
| ▸ | HTR1D | P28221 | 3/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.94 |
| ▸ | DRD1 | P21728 | 3/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | TP53 | P04637 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mianserin SCHEMBL23326358 | 0.97 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL353397 | 0.97 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL9122085 | 0.97 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL29356897 | 0.97 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL18020 | 0.97 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL340474 | 0.96 | MEN1 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL8344416 | 0.96 | DRD3 (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL9752060 | 0.96 | DRD3 (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL29366576 | 0.96 | MEN1 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL11336834 | 0.96 | HTR2A (0.97) | DRD3HTR2ADRD2HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899192-A | Synthesis method of mianserin hydrochloride | 仁和堂药业有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-117777146-B | Mirabilin hydrochloride monohydrate crystal form I and preparation method thereof | 仁和堂药业有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119176757-A | Preparation method of mianserin hydrochloride intermediate and derivative thereof | 四川青木制药有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118852173-A | Novel mianserin hydrochloride crystal form and preparation method thereof | 南京桦冠生物技术有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-117820319-A | Novel crystal form of mianserin hydrochloride and preparation method thereof | 仁和堂药业有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117777144-A | Mirabilin hydrochloride novel crystal form II and preparation method thereof | 仁和堂药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117777146-A | Novel crystal form I of mianserin hydrochloride monohydrate and preparation method thereof | 仁和堂药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | MERCK SHARP & DOHME CORP. (US) | 2022-05-31 | — | — | US | claimed |
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-22 | — | — | US | claimed |
| CN-113820424-A | HPLC-MS/MS method for simultaneously determining concentration of 14 antidepressants in human plasma | 厦门市仙岳医院(厦门市精神卫生中心) | 2021-12-21 | — | — | CN | claimed |
| EP-0923370-B1 | ACETYL CHOLINE ESTERASE INHIBITORS FOR TREATING AND DIAGNOSING SLEEP DISORDERED BREATHING | CURAPATH AB (SE) | 2005-11-16 | — | — | EP | claimed |
| US-20050181049-A1 | Composition and method for enhancing bioavailability | ALZA CORPORATION | 2005-08-18 | — | — | US | claimed |
| WO-2005051358-A1 | COMPOSITION AND METHOD FOR ENHANCING BIOAVAILABILITY | ALZA CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2005004855-A1 | TREATMENT OF PREMATURE EJACULATION | WORLDWIDE PE PATENT HOLDCO PTY LTD (AU) | 2005-01-20 | — | — | WO | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004076675-A2 | GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS | JOHNS HOPKINS UNIVERSITY (US) | 2004-09-10 | — | — | WO | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0651638-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT FOR SEROTONIN DEPLETION ILLNESS | IVY, Mary Elisabeth (ZA) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002138-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT FOR SEROTONIN DEPLETION ILLNESS | IVY, MARY, ELIZABETH (ZA) | 1994-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | NLN, CASP3, BAX | CHRM2 2419/4885CHRM1 3445/4885SLC6A2 482/4885 |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | PDE8B, RPS27A, PDE8A | CHRM2 1284/4885CHRM1 1619/4885SLC6A2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.